- Bayer Group
- About Bayer
- Brand & Values
- Strategic Alignment
- Outlook and Targets
- Opportunity and Risk Report
- Corporate Governance
- Articles of Incorporation
- Board of Management
- Supervisory Board
- Sustainability and Commitment
- Listing and Key Figures
- Share Price
- Capital Increase
- Stockholders' Portal
- Ownership Structure
- Stock Programs
- Stock History
- Annual Stockholders’ Meeting 2018
- Live Events
- Investor Conferences
- Stockholders' Meeting
- Press Conferences
- Other Presentations
- Inside Information
- Investor News
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
Bayer is a life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are helping find solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our corporate purpose: „Bayer: Science for a Better Life”.
|Total dividend payment||2,233||2,315||+3.7|
|Dividend per share (€)||2.70||2.80||+3.7|
|Number of employees3 (Dec. 31)||99,592||99,820||+0.2|
|Personnel expenses (including pension expenses) (€ million)||9,459||9,528||+0.7|
|Proportion of women in senior management (%)||31||32|
|Proportion of employees with health insurance (%)||98||98|
|Fluctuation (voluntary / total) (%)||4.8 / 13.2||4.8 / 10.4|
|Hours of vocational and ongoing training per employee||23.0||23.4||+1.7|
2016 figures restated
1 For definitions of the indicators see Annual Report 2017, Chapter "Alternative Performance Measures Used by the Bayer Group."
2 Group total 2016 including Covestro
3 Employees calculated as full-time equivalents (FTEs)
4 Number of incidents in which chemicals leak from their primary container, such as pipelines, pumps, tanks or drums, per 200,000 working hours
5 Quotient of total energy consumption and manufactured sales volume; Bayer excluding Currenta
6 Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and cooling (according to the market-based method); portfolio-adjusted in accordance with the GHG Protocol
7 Bayer excluding Currenta
Current Investor News
The capital stock of Bayer AG, amounting to Euro 2,387,333,027.84, is divided into 932,551,964 no-par registered shares. The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.
|Security Identification No.|
|Bloomberg||Xetra ®||BAYN GY|
|Frankfurter Wertpapierbörse||BAYN GF|
Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.
Bayer stock is listed on all the German stock exchanges.
Information about the dividend for fiscal 2017
The Annual Stockholders’ Meeting on May 25, 2018 resolved to use of the distributable profit for the fiscal year 2017 of EUR 2,900,000,000.00 an amount of EUR 2,402,253,862.40 to pay a dividend of EUR 2.80 per no-par share on the 857,947,808 no-par shares entitled to the dividend. The dividend yield calculated on the share price at year end 2017 amounts to 2.7 percent.
Stock ownership by region
Our ownership structure shows the international distribution of our capital stock. The highest proportion of our outstanding shares, almost 31 percent, is held by investors in the United States and Canada, followed by Germany with approx. 22 percent. From a regional perspective, Bayer has a stable ownership structure that has altered only slightly in recent years.
Ownership Structure by Country
Taking the acquisition of Monsanto into account, the rating agencies have confirmed the following ratings:
|Rating agency||Long-term rating||Short-term rating||Outlook|
|S&P Global Ratings||BBB||A2||stable|
(published on November 13, 2018 in the Interim Report Q3 2018)
We confirm the outlook for the Bayer Group that was updated in the second quarter of 2018 to reflect the acquisition, although the forecasts for Consumer Health and Animal Health are now becoming increasingly ambitious.
Forecast for Key Financial Data of the Group for 2018
|Closing rates on September 30, 2018||Currency-adjusted|
|Sales||More than €39 billion||Increase by a mid-single-digit percentage1|
|Development of EBITDA before special items||Increase by a low- to mid-single-digit percentage||Increase by a high-single-digit percentage|
|Development of core earnings per share||€5.70 – €5.90||Decrease by a high-single-digit percentage|
1 Adjusted for currency and portfolio effects
This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer Investor Relations
Dr. Jürgen Beunink